April 25, 2005 Until the final half-hour, biotech couldn’t seem to buy a friend on Monday, as it sank progressively lower as the session moved on. Then, with little time left, it suddenly gathered strength and began to pare its losses, almost getting back to breakeven. At the closing bell, the Centient Biotech 200 was still about 2 points negative at 3177.47 a loss of .07% on the day. The S&P 500 was up .87%, and Nasdaq gained .96%. Ceregen announced promising results from an early test of a gene therapy for Alzheimer’s, Millennium keeps advancing Velcade for other cancer indications, Sepracor cut its Q1 loss while everyone watches its launch of Lunestra, Prestwick filed for an IPO, Isolagen took a hit after its new CEO quit unexpectedly, and Pozen keeps soaring. More detail...
